increased anxiety on glp 1 GLP-1 Agonists Can Be Heaven or Hell Dependent Upon Dopaminergic Genetic/Epigenetic Antecedents[v1] Does GLP-1 Cause Depression and

The question behind the question is usually: "How much longer will I be able to get compounded semaglutide at this price?" The pattern we see: patients conflate three separate timelines: Patent expiration (2031-2033 for the formulations that matter) FDA shortage list removal (expected late 2026 to Q1 2027) Generic market entry (2027 for oral, 2031-2032 for injectable, assuming no patent challenges) The timeline that affects current compounded access is number 2, not number 1

Taking into account the above-mentioned considerations on cost and safety aspects, oral small molecule agonists stimulating endogenous GLP-1 secretion by intestinal L-cells may offer a promising alternative for developing new treatments for Type 2 diabetes and obesity

The reality: These medications are expensive to research, manufacture, and test Insurance coverage is limited or nonexistent for many patients In some cases, a compounding pharmacy may offer customized alternatives when medically appropriatesuch as different doses or formulations for patients with sensitivities

Strong consumer demand and lack of competition has kept prices high, with out-of-pocket costs reaching over $1,000 per month before insurance, rebates and discounts

8% with placebo, Table 3)